AstraZeneca PLC (AZNs)

BATS Europe
Currency in SEK
1,318.75
-7.75(-0.58%)
Closed·
AZNs Scorecard
Full Analysis
2 analysts have revised their earnings upwards for the upcoming period
AZNs is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1,313.001,322.50
52 wk Range
1,270.751,795.75
Key Statistics
Edit
Bid/Ask
1,298.50 / 1,280.50
Prev. Close
1,326.5
Open
1,322.5
Day's Range
1,313-1,322.5
52 wk Range
1,270.75-1,795.75
Volume
241
Average Vol. (3m)
314
1-Year Change
-20.62%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AZNs Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high P/E ratio relative to near-term earnings growth
Show more

AstraZeneca PLC Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Employees
94300
Market
Sweden

Compare AZNs to Peers and Sector

Metrics to compare
AZNs
Peers
Sector
Relationship
P/E Ratio
26.7x17.3x−0.5x
PEG Ratio
1.190.010.00
Price / Book
5.1x3.1x2.6x
Price / LTM Sales
3.8x2.3x2.9x
Upside (Analyst Target)
-7.5%51.4%
Fair Value Upside
Unlock24.8%9.5%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 5.01%
Dividend Yield
2.54%
Industry Median 1.19%
Annualized Payout
33.02
Paid unevenly
5-Years Growth
+2.06%
Growth Streak

Earnings

Latest Release
Apr 29, 2025
EPS / Forecast
2.49 / 2.21
Revenue / Forecast
13.59B / 13.77B
EPS Revisions
Last 90 days

People Also Watch

89.87
SASY
+1.16%
434.4
NOVOb
+0.35%
879.50
HSBA
+0.96%
376.90
OREP
+1.15%
1,682.000
RHMG
+5.65%

FAQ

What Is the AstraZeneca PLC (AZNs) Stock Price Today?

The AstraZeneca PLC stock price today is 1,318.75

What Stock Exchange Does AstraZeneca PLC Trade On?

AstraZeneca PLC is listed and trades on the BATS Europe stock exchange.

What Is the Stock Symbol for AstraZeneca PLC?

The stock symbol for AstraZeneca PLC is "AZNs."

Does AstraZeneca PLC Pay Dividends? What’s The Current Dividend Yield?

The AstraZeneca PLC dividend yield is 2.54%.

What Is the AstraZeneca PLC Market Cap?

As of today, AstraZeneca PLC market cap is 2.04T.

What Is AstraZeneca PLC's Earnings Per Share (TTM)?

The AstraZeneca PLC EPS (TTM) is 5.01.

When Is the Next AstraZeneca PLC Earnings Date?

AstraZeneca PLC will release its next earnings report on Jul 24, 2025.

From a Technical Analysis Perspective, Is AZNs a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.